Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01884688 · ClinicalTrials.gov registry record · Phase 2
UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01884688 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 3 participants.
The verdict
NCT01884688, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and in vivo persistence and expansion of autologous and expansion of autologous, ex vivo expanded-natural killer(ENK) cells.
Interventions
- DRUG ENK Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-04 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01884688
The ClinicalTrials.gov registry entry for NCT01884688 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ENK Cell Infusion is the first listed.
NCT01884688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01884688 about?
NCT01884688 is a clinical study titled "UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma". The purpose of this study is to determine the safety and in vivo persistence and expansion of autologous and expansion of autologous, ex vivo expanded-natural killer(ENK) cells.
What is the current status of trial NCT01884688?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2013-04. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01884688?
The interventions under investigation include: ENK Cell Infusion (DRUG).
Who is sponsoring clinical trial NCT01884688?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.